RT @KDAO2011: IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PC
Tweet Content
IL-17i for GCA? TitAIN study met all endpoints!
phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB
👉effective sustained remission
👉longer time to GCA flare
👉lower dose of steroids by week 52
👉no increase in AEs
#ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
Show on Archive Page
On
Display in Search Results
On
PDQ
Off